- Rocket Lab revenue surged 62% year over year to a record $234 million in Q2 2026, driven overwhelmingly by its Space Systems business.
- RKLB stock fell after earnings as Q3 margin guidance disappointed and uncertainty increased around the timing of Neutron's first launch.
- Citizens reiterated its Market Outperform rating and $130 Rocket Lab stock price target, suggesting substantial upside from Monday's $80.04 close.
Rocket Lab (NASDAQ: RKLB) stock is in focus on Tuesday after investors delivered a surprisingly negative verdict on another record quarter from the space company.
RKLB shares closed Monday down 3.4% at $80.04 before falling another 7% in extended trading. The selloff came despite Rocket Lab reporting record quarterly revenue of about $234 million, up 62% year over year, and issuing Q3 revenue guidance above Wall Street expectations.
The problem was not growth. Investors instead focused on what that growth is costing Rocket Lab and whether its much-anticipated Neutron rocket can begin flying on schedule.
That makes Tuesday’s analyst reaction particularly interesting. Citizens reiterated its Market Outperform rating and $130 price target for RKLB stock, maintaining a bullish long-term view even as the market focuses on Rocket Lab’s near-term margin and execution risks.
Why Is Rocket Lab Stock Falling After Q2 Earnings?
Rocket Lab’s Q2 numbers initially look difficult to reconcile with the drop in RKLB stock. Revenue reached a quarterly record, with Space Systems accounting for roughly 81% of sales. More importantly, Rocket Lab expects another record in Q3, forecasting revenue between $250 million and $265 million.
However, the quality of that incremental revenue has become the bigger question.
Rocket Lab expects Q3 gross margin of only 29% to 31%, substantially below the 37.6% Wall Street estimate cited by Reuters. Management attributed part of the pressure to a larger contribution from lower-margin satellite-platform programs.
In other words, Rocket Lab is selling more, but investors are being asked to tolerate weaker near-term margins while the company simultaneously spends heavily on Neutron. For a stock carrying an aggressive growth valuation, that combination matters.
Rocket Lab’s Neutron Rocket Is Becoming the Main RKLB Stock Catalyst
Neutron remains the most important piece of the Rocket Lab investment story.
The reusable medium-lift rocket would move Rocket Lab beyond Electron’s small-launch niche and allow it to compete for substantially larger commercial, constellation and U.S. national-security missions.
But the timeline has become less certain.
Rocket Lab previously targeted Neutron’s inaugural flight for the fourth quarter of 2026. Its latest update instead said first-stage tank production is aligned with getting Neutron to the launch pad during Q4, without providing a firm maiden-flight date.
CEO Peter Beck acknowledged that the window for a year-end launch is narrowing, although CFO Adam Spice indicated the company still hopes to launch within that timeframe. As reported by Reuters
That distinction appears to be one of the biggest reasons RKLB stock reacted negatively. The market is no longer simply valuing Neutron as a future product. Investors increasingly need evidence that Rocket Lab can move from development into reliable commercial operations.
Citizens Keeps $130 Rocket Lab Stock Price Target
Despite those concerns, Citizens remains firmly bullish on Rocket Lab. Analyst Trevor Walsh reiterated a Market Outperform rating and $130 price target, arguing that continued progress is reducing some of the execution risk surrounding Neutron. From Monday’s $80.04 closing price, a $130 target represents approximately 62% upside.
The bullish case goes beyond Neutron.
Electron continues to establish Rocket Lab’s position in the launch market, while Space Systems has quietly become the company’s primary revenue engine. That diversification means Rocket Lab is increasingly becoming an integrated space infrastructure company rather than a business dependent entirely on launch frequency.
The company’s record $2.36 billion backlog reinforces that argument. The backlog was up 137% year over year, providing significant visibility into future revenue. But backlog and revenue growth alone will not settle the debate surrounding RKLB stock. The next stage is proving that scale can eventually produce attractive margins and cash flow.
Rocket Lab’s Iridium Deal Could Expand Its Space Ambitions
Another major part of the longer-term Rocket Lab story is its pending acquisition of Iridium Communications. Citizens views the proposed transaction as potentially filling an important gap in Rocket Lab’s end-to-end space strategy by adding spectrum, an operating satellite network and recurring services to its existing launch and spacecraft operations.
If completed successfully, the combination would broaden Rocket Lab’s exposure beyond building and launching space hardware. It could also create a more recurring revenue base, something that would become increasingly important as investors assess whether Rocket Lab can justify its premium valuation.
RKLB Stock Outlook: Neutron Matters More Than Another Revenue Record
Rocket Lab’s Q2 earnings demonstrate that demand is not currently the company’s biggest problem. Revenue is growing rapidly, backlog has reached a record and Q3 sales could set another quarterly high.
The harder question is profitability.
Rocket Lab is entering a period where Neutron spending, weaker Space Systems margins and execution risk are colliding with a valuation that already assumes significant future success. That explains why record revenue could coexist with a sharp post-earnings decline.
For RKLB stock, the next major catalyst may therefore be less about whether quarterly revenue reaches $250 million or $260 million and more about what happens at the Neutron launch pad.
A successful progression through qualification testing, pad delivery and ultimately the maiden flight would remove one of the largest uncertainties hanging over Rocket Lab’s valuation. Another meaningful delay could do the opposite. Citizens’ $130 target shows that Wall Street’s longer-term bull case remains alive. The post-earnings selloff shows investors are no longer willing to price that future without demanding evidence that Neutron can deliver it.
Rocket Lab stock fell despite strong Q2 revenue growth because investors focused on weaker Q3 gross margin guidance, widening adjusted EBITDA losses and uncertainty surrounding the timing of Neutron’s maiden launch. With RKLB carrying a high growth valuation, expectations going into earnings were already elevated.
Citizens reiterated its Market Outperform rating and $130 price target for RKLB stock following the Q2 results. Based on Monday’s $80.04 closing price, the target implies roughly 62% upside, although analyst price targets are not guarantees of future performance.
Rocket Lab is targeting Q4 2026 for Neutron to reach the launch pad. The company still hopes to conduct the maiden flight before the end of 2026, but management has acknowledged that the available launch window is narrowing as testing and qualification work continues.
